The new Council will bring together industry and patient advocates to help steer and broaden the Association’s strategic thinking, ensuring a more patient-centric future strategy, policy and priorities.
Tom takes his place alongside Charlotte Augst from National Voices, Emily Crossley from Duchenne UK, Jane Lyons from Cancer52, Hilary Reynolds from the Association of Medical Research Charities, Jayne Spink from Prostate Cancer Research, Bob Stevens from the MPS Society, and Neil Tester from the Richmond Group.
The Patient Advisory Council members will join the ABPI’s Board meeting today [Tuesday 7 September] for the first time.
Understanding the patient experience
Announcing the first members of the Council, Colette Goldrick, Executive Director of Strategy, Research & Partnerships at the ABPI, said:
“We have had an overwhelming response to our search for a new Patient Advisory Council, and we are really proud to name these eight passionate experts as our inaugural members.
“The Council was formed with the sole purpose of ensuring the Association, our Board and the industry at large has a greater understanding of the patient experience, and how our work can help improve the lives of patients and their families. We’re excited to get started.”
Council members will provide patient perspectives across policy topics relevant to both industry and patients, such as outcomes-focused healthcare, medicines pricing, patient engagement in health technology assessment (HTA), healthcare data and collaboration.
Work is not yet complete
Tom said: “I’m delighted to join the Council and look forward to participating fully in its activities. As CEO of Meningitis Now, I expect to draw on the charity’s extensive research and campaigning that has already helped with the development and introduction of five lifesaving vaccines now available on the NHS – reducing the number of UK meningitis cases every year since the 1990s.
“By sharing the knowledge and insights we learn every day as the people’s voice for meningitis, and by working with other leading patient groups, I hope we can shape and positively influence the vital work of the UK pharmaceutical sector.”
The ABPI exists to make the UK the best place in the world to research, develop and use new medicines and vaccines. It represents companies of all sizes who invest in discovering the medicines of the future.
Members supply cutting edge treatments that improve and save the lives of millions of people and work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines.
Every day, the ABPI partner with organisations in the life sciences community and beyond to transform lives across the UK.